Jason Gray

Title: Jason Gray - Innovator in Pharmaceutical Chemistry

Introduction

Jason Gray is a notable inventor based in Hertfordshire, GB. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel crystalline forms of clopidogrel, a platelet aggregation inhibitor. His work has implications for the treatment and management of various cardiovascular disorders.

Latest Patents

Jason Gray holds a patent for "Crystalline polymorphs of clopidogrel." This invention relates to novel crystalline forms of clopidogrel, specifically hydrogen bromide salts identified as polymorph forms 1, 2, and 3. The patent outlines processes for preparing these forms, pharmaceutical compositions that include them, and their uses in inhibiting platelet aggregation. These compositions are particularly useful for treating conditions such as thrombosis, atherothrombosis, ischaemic stroke, and myocardial infarction, among others.

Career Highlights

Jason Gray is currently associated with Generics (UK) Limited, where he continues to advance his research and development efforts. His work has led to important advancements in the pharmaceutical industry, particularly in the formulation of effective treatments for cardiovascular diseases.

Collaborations

Jason collaborates with talented professionals in his field, including Ramakrishnan Arul and Ajay Singh Rawat. Their combined expertise contributes to the innovative research and development efforts at Generics (UK) Limited.

Conclusion

Jason Gray's contributions to pharmaceutical chemistry, particularly through his patent on clopidogrel polymorphs, highlight his role as an important inventor in the field. His work not only advances scientific knowledge but also has the potential to improve patient outcomes in cardiovascular health.